The bad news is it was on bardoxolone. Tweetorial catch-up here.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
The bad news is it was on bardoxolone. Tweetorial catch-up here.
✳️ #TenTweetNephJC ✳️
— Nephrology Journal Club (@NephJC) January 28, 2023
This week CARDINAL - the largest ever RCT in patients with Alport Syndrome 🧵👇 pic.twitter.com/wrAxJoz1GJ